Active	Status	Sponsor type	Region	Phase	Filter
5 Active 0 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   - « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Lewis, Joanne
ACTION, NCT05580562: ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the Study) Jan 2026 - Dec 2026: Final data from ACTION trial for newly diagnosed H3 K27M-mutant diffuse glioma Jan 2025 - Mar 2025: Interim data from ACTION trial for newly diagnosed H3 K27M-mutant diffuse glioma	Recruiting	3	450	Europe, Canada, Japan, US, RoW	Dordaviprone (ONC201), Dordaviprone (ONC201) + Placebo, Placebo	Chimerix	H3 K27M, Glioma	08/26	08/26
CLINGLIO, NCT04250922 / 2018-000365-37: LAM561 With RT and TMZ for Adults With Glioblastoma	Active, not recruiting	2/3	140	Europe, RoW	LAM561, TMZ, RT	Laminar Pharmaceuticals, Laboratory Corporation of America, Northern Institute for Cancer Research, Newcastle, Theradis pharma, LIPODOM THERAPEUTICS	Primary Glioblastoma, Glioblastoma Multiforme	10/24	05/25
NCT04359745: Improving Treatment of Glioblastoma: Distinguishing Progression From Pseudoprogression	Recruiting	N/A	500	Europe		Guy's and St Thomas' NHS Foundation Trust, King's College London	Glioblastoma	05/24	05/25
NCT04274283: Tessa Jowell BRAIN MATRIX - Platform Study	Recruiting	N/A	1000	Europe	Matched Tumour and Blood Sample - Research Pathway, Matched Tumour and Blood Sample - NHS GMS pathway	University of Birmingham, The Brain Tumour Charity, University of Oxford, University of Edinburgh, Genomics England	Glioma	03/26	03/27
Fiona, Harris
CLINGLIO, NCT04250922 / 2018-000365-37: LAM561 With RT and TMZ for Adults With Glioblastoma	Active, not recruiting	2/3	140	Europe, RoW	LAM561, TMZ, RT	Laminar Pharmaceuticals, Laboratory Corporation of America, Northern Institute for Cancer Research, Newcastle, Theradis pharma, LIPODOM THERAPEUTICS	Primary Glioblastoma, Glioblastoma Multiforme	10/24	05/25

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Lewis, Joanne
ACTION, NCT05580562: ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the Study) Jan 2026 - Dec 2026: Final data from ACTION trial for newly diagnosed H3 K27M-mutant diffuse glioma Jan 2025 - Mar 2025: Interim data from ACTION trial for newly diagnosed H3 K27M-mutant diffuse glioma	Recruiting	3	450	Europe, Canada, Japan, US, RoW	Dordaviprone (ONC201), Dordaviprone (ONC201) + Placebo, Placebo	Chimerix	H3 K27M, Glioma	08/26	08/26
CLINGLIO, NCT04250922 / 2018-000365-37: LAM561 With RT and TMZ for Adults With Glioblastoma	Active, not recruiting	2/3	140	Europe, RoW	LAM561, TMZ, RT	Laminar Pharmaceuticals, Laboratory Corporation of America, Northern Institute for Cancer Research, Newcastle, Theradis pharma, LIPODOM THERAPEUTICS	Primary Glioblastoma, Glioblastoma Multiforme	10/24	05/25
NCT04359745: Improving Treatment of Glioblastoma: Distinguishing Progression From Pseudoprogression	Recruiting	N/A	500	Europe		Guy's and St Thomas' NHS Foundation Trust, King's College London	Glioblastoma	05/24	05/25
NCT04274283: Tessa Jowell BRAIN MATRIX - Platform Study	Recruiting	N/A	1000	Europe	Matched Tumour and Blood Sample - Research Pathway, Matched Tumour and Blood Sample - NHS GMS pathway	University of Birmingham, The Brain Tumour Charity, University of Oxford, University of Edinburgh, Genomics England	Glioma	03/26	03/27
Fiona, Harris
CLINGLIO, NCT04250922 / 2018-000365-37: LAM561 With RT and TMZ for Adults With Glioblastoma	Active, not recruiting	2/3	140	Europe, RoW	LAM561, TMZ, RT	Laminar Pharmaceuticals, Laboratory Corporation of America, Northern Institute for Cancer Research, Newcastle, Theradis pharma, LIPODOM THERAPEUTICS	Primary Glioblastoma, Glioblastoma Multiforme	10/24	05/25